Q1 EPS Forecast for Cullinan Therapeutics Reduced by Analyst

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – Stock analysts at HC Wainwright lowered their Q1 2027 earnings per share (EPS) estimates for Cullinan Therapeutics in a research note issued to investors on Friday, September 25th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.95) per share for the quarter, down from their prior estimate of ($0.77). HC Wainwright currently has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.08) per share. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q2 2027 earnings at ($0.96) EPS, Q3 2027 earnings at ($0.98) EPS, Q4 2027 earnings at ($1.00) EPS and FY2027 earnings at ($3.89) EPS.

CGEM has been the topic of a number of other research reports. Wedbush upped their price target on shares of Cullinan Therapeutics from $39.00 to $42.00 and gave the company an “outperform” rating in a research note on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. TD Cowen upgraded shares of Cullinan Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Wall Street Zen downgraded shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 13th. Finally, BTIG Research reiterated a “buy” rating and issued a $40.00 price target on shares of Cullinan Therapeutics in a research report on Friday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.71.

Cullinan Therapeutics Stock Performance

NASDAQ CGEM opened at $15.35 on Tuesday. The stock has a 50 day moving average price of $19.62 and a 200-day moving average price of $16.72. Cullinan Therapeutics has a one year low of $5.68 and a one year high of $23.19. The company has a market capitalization of $987.93 million, a P/E ratio of -4.95 and a beta of 0.02.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.01).

Insider Activity

In other news, insider Jennifer Michaelson sold 8,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $21.57, for a total transaction of $172,560.00. Following the completion of the sale, the insider directly owned 158,844 shares of the company’s stock, valued at approximately $3,426,265.08. The trade was a 4.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 46,000 shares of company stock worth $922,920 over the last ninety days. 8.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Cullinan Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Cullinan Therapeutics during the 2nd quarter worth $95,289,000. Blue Owl Capital Holdings LP purchased a new stake in shares of Cullinan Therapeutics in the 2nd quarter worth $28,039,000. Boothbay Fund Management LLC bought a new position in shares of Cullinan Therapeutics during the 4th quarter worth $12,803,000. Boone Capital Management LLC purchased a new position in shares of Cullinan Therapeutics during the second quarter valued at $12,828,000. Finally, Elmind Capital LP bought a new stake in shares of Cullinan Therapeutics in the second quarter valued at about $12,564,900. Institutional investors own 86.31% of the company’s stock.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company’s approach combines internally developed drug candidates with licensed or acquired programs and partnerships intended to address areas of significant unmet medical need.

Its pipeline has included zipalertinib, an oral tyrosine kinase inhibitor being developed for patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations.